Frontlight ResearchEarly access
Not yet recruitingNo phase
Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions(EXIT-SEP REAL)
Key facts
- Who runs it
- Southeast University, China
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 5,400 people, planned
- Started
- 1 Aug 2025
- Expected to end
- Sept 2027
- Type of study
- Observational
- Record updated
- 17 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Hospitalized patients aged ≥18 years
- Sepsis diagnosis meeting Sepsis-3 criteria
- Informed consent signed by patient or legally authorized representative
Who cannot take part
- Patients with a prior history of sepsis
- Sepsis diagnosis >48 hours prior to enrollment
- Current participation in clinical trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Xuebijing injection (XBJ) showed proven efficacy in the EXIT-SEP trial (NCT03238742), lowering 28-day mortality. However, its real-world effectiveness requires validation due to the trial's strict criteria. Broader clinical evaluation is imperative.
The group in the trial
- Xuebijing Group
The Xuebijing group consisted of sepsis patients who received both Xuebijing injection and guideline-concordant therapy. Researchers did not provide any additional interventions, but instead observed and documented the clinical outcomes and treatment effects of Xuebijing injection in combination with standard therapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions: A Patient Registry
- Record updated
- 17 July 2025